DC 欄位 | 值 | 語言 |
dc.contributor | 臺大公衛學院-預防醫學研究所;臺大醫院;臺大醫院-內科部;臺大醫院雲林分院;臺大醫學院;臺大醫學院-醫學系; | en |
dc.contributor.author | CHIA-HSUIN CHANG | en_US |
dc.contributor.author | JOU-WEI LIN | en_US |
dc.contributor.author | Wu, Li-Chiu | en_US |
dc.contributor.author | Lai, Mei-Shu | en_US |
dc.contributor.author | LEE-MING CHUANG | en_US |
dc.contributor.author | KIN-WEI CHAN | en_US |
dc.creator | Chang, Chia-Hsuin;Lin, Jou-Wei;Wu, Li-Chiu;Lai, Mei-Shu;Chuang, Lee-Ming;Arnold Chan, K. | en |
dc.creator | 賴美淑 ;張家勳 ;莊立民 ;林昭維 | zh-tw |
dc.date | 2012 | en |
dc.date.accessioned | 2014-02-14T03:50:58Z | - |
dc.date.accessioned | 2018-07-11T06:35:09Z | - |
dc.date.available | 2014-02-14T03:50:58Z | - |
dc.date.available | 2018-07-11T06:35:09Z | - |
dc.date.issued | 2012 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw//handle/246246/258827 | - |
dc.identifier.uri | http://ntur.lib.ntu.edu.tw/bitstream/246246/258827/1/index.html | - |
dc.description.abstract | The objective of this nationwide case-control study was to evaluate the risk of specific malignancy in diabetic patients who received thiazolidinediones (TZDs). A total of 606,583 type 2 diabetic patients, age 30 years and above, without a history of cancer were identified from the Taiwan National Health Insurance claims database during the period between January 1 2000 and December 31 2000. As of December 31 2007, patients with incident cancer of liver, colorectal, lung, and urinary bladder were included as cases and up to four age- and sex-matched controls were selected by risk-set sampling. Logistic regression models were applied to estimate the odds ratio (OR) and 95% confidence interval (CI) between TZDs and cancer incidence. A total of 10,741 liver cancer cases, 7,200 colorectal cancer cases, and 70,559 diabetic controls were included. A significantly lower risk of liver cancer incidence was found for any use of rosiglitazone (OR: 0.73, 95% CI: 0.65-0.81) or pioglitazone (OR: 0.83, 95% CI: 0.72-0.95), respectively. The protective effects were stronger for higher cumulative dosage and longer duration. For colorectal cancer, rosiglitazone, but not pioglitazone, was associated with a significantly reduced risk (OR: 0.86; 95% CI: 0.76-0.96). TZDs were not associated with lung and bladder cancer incidence, although a potential increased risk for bladder cancer with pioglitazone use =3 years could not be excluded (OR: 1.56; 95% CI: 0.51-4.74). Conclusion: The use of pioglitazone and rosiglitazone is associated with a decreased liver cancer incidence in diabetic patients. The effects on occurrence of specific cancer types may be different for pioglitazone and rosiglitazone. (HEPATOLOGY 2012;) | en_US |
dc.format.extent | 99 bytes | - |
dc.format.mimetype | text/html | - |
dc.language | en-us | en |
dc.relation | Hepatology, 55(5), 1462-1472 | en_US |
dc.relation.ispartof | Hepatology | en_US |
dc.subject.classification | [SDGs]SDG3 | - |
dc.subject.other | insulin; metformin; oral antidiabetic agent; pioglitazone; rosiglitazone; sulfonylurea; adult; aged; article; bladder cancer; cancer incidence; cancer risk; case control study; colorectal cancer; controlled study; disease association; female; human; liver cancer; lung cancer; major clinical study; male; non insulin dependent diabetes mellitus; priority journal; side effect; Taiwan; treatment duration; Administration, Oral; Adult; Age Distribution; Case-Control Studies; Colorectal Neoplasms; Confidence Intervals; Databases, Factual; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Hypoglycemic Agents; Liver Neoplasms; Male; Middle Aged; Odds Ratio; Prevalence; Risk Assessment; Severity of Illness Index; Sex Distribution; Survival Analysis; Taiwan; Thiazolidinediones | - |
dc.title | Association of thiazolidinediones with liver cancer and colorectal cancer in type 2 diabetes mellitus | en_US |
dc.identifier.doi | 10.1002/hep.25509 | - |
item.fulltext | with fulltext | - |
item.grantfulltext | open | - |
dc.relation.pages | 1462-1472 | en_US |
dc.relation.journalvolume | 55 | en_US |
dc.relation.journalissue | 5 | en_US |
dc.identifier.uri.fulltext | http://ntur.lib.ntu.edu.tw/bitstream/246246/258827/1/index.html | - |
item.grantfulltext | open | - |
item.fulltext | with fulltext | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Internal Medicine-NTUH | - |
crisitem.author.dept | Epidemiology and Preventive Medicine | - |
crisitem.author.orcid | 0000-0003-0024-6177 | - |
crisitem.author.orcid | 0000-0001-7614-3903 | - |
crisitem.author.orcid | 0000-0003-0978-2662 | - |
crisitem.author.orcid | 0000-0001-8161-1986 | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
crisitem.author.parentorg | College of Public Health | - |
顯示於: | 醫學系
|